Perfuze

Perfuze operates in the neurovascular medical-device segment, focusing on aspiration thrombectomy for acute ischemic stroke rather than building a broad portfolio across unrelated procedural areas. Its core proposition is an integrated access-and-aspiration workflow: Millipede catheters address clot ingestion and aspiration, while Zipline access catheters are designed to support navigation and delivery. The Millipede88’s large 0.088-inch lumen and FDA clearance for standalone direct aspiration provide a specific product distinction, while the MARRS pivotal-trial program supplies clinical evidence beyond a purely engineering-led positioning. The company’s €47.5 million in disclosed financing and backing from EQT Life Sciences, Seroba Life Sciences, SV Health Investors, and EarlyBird indicate substantial specialist-investor support for a focused medtech commercialization strategy. Perfuze’s competitive position is therefore best characterized as a focused, clinically advancing challenger in aspiration thrombectomy, with differentiation tied to catheter bore size, integrated procedural components, and regulatory progress rather than demonstrated scale.

Perfuze’s trajectory shows a progression from early technical formation to clinical validation and U.S. commercialization. The company was founded in 2018, raised a $3.4 million seed round in 2019, and followed with a $25.7 million Series A announced on Feb 7, 2022. Its largest disclosed financing came on Mar 13, 2025, when a $23.9 million venture round accompanied FDA 510(k) clearance for Zipline access catheters. Product development has expanded from the Millipede aspiration platform to an integrated system including access catheters and tubing. Clinical execution became a central inflection point in 2025: enrollment in the pivotal U.S. study was completed on Apr 22, 2025, preliminary MARRS results were presented on Jul 16, 2025, and final results were announced on Aug 31, 2026. FDA clearance for Millipede88 on Mar 17, 2026 marked a further transition from development into limited U.S. market release. Joe Rotger’s appointment as Executive Vice President of Sales in April 2025 and ongoing hiring for sales operations suggest commercial infrastructure is being built. However, the company’s employee count, revenue, customer base, and broader launch scale remain unclear.